



Equivalent of Form PTO/SB/08a (01-08)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Shee

1

of

1

plete if Known

Application Number	10/782,664
Filing Date	February 18, 2004
First Named Inventor	MONTERO-JULIAN, Felix A.
Art Unit	1644
Examiner Name	DIBRINO, Marianne
Attorney Docket Number	2512.0210001/KWM/C-K (052-183-NOND)

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No.*	Foreign Patent Document Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
/M.D./	FP14	WO 99/28748 A2	06/10/1999	Isis Innovation Ltd.
/M.D./	FP15	WO 99/50637 A2	10/07/1999	Ludwig Institute for Cancer Research; The Chancellor, Masters and Scholars of the University of Oxford
/M.D./	FP16	WO 00/25813 A1	05/11/2000	Dana-Farber Cancer Institute; The Whitehead Institute for Biomedical Research

843261_1.doc

Examiner Signature	/Marianne DiBrino/	Date Considered	02/19/2009
-----------------------	--------------------	--------------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.4. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. FAXING FEES, SEND TO: TOLC-Complaints@uspto.gov, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/782,664
				Filing Date	February 18, 2004
				First Named Inventor	MONTERO-JULIAN, Felix A.
				Art Unit	1644
				Examiner Name	DIBRINO, Marianne
Sheet	1	of	1	Attorney Docket Number	2512.0210001/KWM/C-K (2052-183-NONP)

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²
/M.D./	NPL50	Du Pasquier, R.A., <i>et al.</i> , "Low Frequency of Cytotoxic T Lymphocytes against the Novel HLA-A*0201-Restricted JC Virus Epitope VP1 ₁₃₆ in Patients with Proven or Possible Progressive Multifocal Leukoencephalopathy", <i>J. Virol.</i> 77:11918-11926, American Society For Microbiology (November 2003)				
/M.D./	NPL51	Hermans, I.F., <i>et al.</i> , "The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo", <i>J. Immunol. Methods</i> 285:25-40, North-Holland Publishing Co. (February 2004)				
/M.D./	NPL52	Mallet-Designe, V.I., <i>et al.</i> , "Detection of Low-Avidity CD4 ⁺ T Cells Using Recombinant Artificial APC: Following the Antiovalbumin Immune Response", <i>J. Immunol.</i> 170:123-131, American Association of Immunologists (January 2003)				
/M.D./	NPL53	Robert, B., <i>et al.</i> , "Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes", <i>Eur. J. Immunol.</i> 30:3165-3170, VCH Verlagsgesellschaft (2000)				
/M.D./	NPL54	European Search Report for European Application No. EP 05 74 5499, completed on April 24, 2008, European Patent Office, The Hague, Netherlands				

844273_1.doc

Examiner Signature	/Marianne DiBrino/	Date Considered	02/19/2009
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with completed consideration to applicant.

¹Applicant's choice citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.